Angiogenesis in hepatocellular carcinoma:mechanisms and anti-angiogenic therapies  

作　　者：Changyu Yao Shilun Wu Jian Kong Yiwen Sun Yannan Bai Ruhang Zhu Zhuxin Li Wenbing Sun Lemin Zheng 

机构地区：[1]Department of Hepatobiliary Surgery,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100043,China [2]Department of Pathology,Peking University People's Hospital,Peking University,Beijing 100044,China [3]Department of Hepatobiliary Pancreatic Surgery,Shengli Clinical Medical College of Fujian Medical University,Fujian Provincial Hospital,Fuzhou 350001,China [4]The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine,School of Basic Medical Sciences,Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education,Health Sciences Center,Peking University,Beijing 100083,China [5]Beijing Tiantan Hospital,China National Clinical Research Center of Neurological Diseases,Advanced Innovation Center for Human Brain Protection,Capital Medical University,Beijing 100050,China

出　　处：《Cancer Biology & Medicine》2023年第1期25-43,共19页癌症生物学与医学（英文版）

基　　金：supported by the National Key Research and Development Program of China(Grant No.2020YFA0803700);the National Natural Science Foundation of China(Grant Nos.91639108,81770272,and 81970425);the Beijing Natural Science Foundation(Grant No.7212044);the Beijing Hospital Authority Youth Program(Grant No.QML20190306)。

摘　　要：Hepatocellular carcinoma(HCC)is the fourth leading cause of cancer-associated death worldwide.Angiogenesis,the process of formation of new blood vessels,is required for cancer cells to obtain nutrients and oxygen.HCC is a typical hypervascular solid tumor with an aberrant vascular network and angiogenesis that contribute to its growth,progression,invasion,and metastasis.Current anti-angiogenic therapies target mainly tyrosine kinases,vascular endothelial growth factor receptor(VEGFR),and plateletderived growth factor receptor(PDGFR),and are considered effective strategies for HCC,particularly advanced HCC.However,because the survival benefits conferred by these anti-angiogenic therapies are modest,new anti-angiogenic targets must be identified.Several recent studies have determined the underlying molecular mechanisms,including pro-angiogenic factors secreted by HCC cells,the tumor microenvironment,and cancer stem cells.In this review,we summarize the roles of pro-angiogenic factors;the involvement of endothelial cells,hepatic stellate cells,tumor-associated macrophages,and tumor-associated neutrophils present in the tumor microenvironment;and the regulatory influence of cancer stem cells on angiogenesis in HCC.Furthermore,we discuss some of the clinically approved anti-angiogenic therapies and potential novel therapeutic targets for angiogenesis in HCC.A better understanding of the mechanisms underlying angiogenesis may lead to the development of more optimized anti-angiogenic treatment modalities for HCC.

关 键 词：ANGIOGENESIS hepatocellular carcinoma pro-angiogenic factors tumor microenvironment anti-angiogenic therapy 

分 类 号：R735.7[医药卫生—肿瘤]